Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 in advanced solid tumors
NCT05701709Phase 1Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2023
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-A2102 in solid tumor (advanced stage), sponsored by Hengrui Therapeutics. Primary endpoints: Number of participants with adverse events at 24 months, Maximum tolerated dose at 12 weeks and 2 more. Started Apr 2023; status: recruiting.
02
Drugs
SHR-A2102
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05701709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701709.